SEC Form 4 · accession 0001209191-15-018139
Dicerna Pharmaceuticals Inc · DRNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Feb 20, 2015
Accepted (ET)
Feb 24, 2015 · 8:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001399529
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Feb 20, 2015 | S | 37,532 | $26.02 | D | 1,719,671 | I | see footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2014.
- F2The securities are held by Skyline Ventures Partners V, L.P. ("Skyline V"), John G. Freund, M.D. and Yasunori Kaneko, M.D. are Managing Directors of Skyline Venture Management V, LLC the general partner of Skyline V and may be deemed to share voting and dispositive power over share held by Skyline V. Stephen Hoffman, M.D., Ph.D. is a former member of Skyline Venture Management V, LLC that has transitioned to an independent consultant of Skyline with no voting or dispositive power over the shares. Each of Drs. Freund and Kaneko disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.